Optimizing Bruton Kinase (BTK) Inhibitors in Relapsed/Refractory (R/R) Mantle Cell Lymphoma - Episode 4

Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

,

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the evolution of BTK inhibitors and how they have changed treatment approaches in clinical practice.